Earnings visibility is difficult due to the multi-faceted nature of Sagent's generic drug business, however, CEO Jeffrey Yordon says he anticipates a strong first quarter after seeing sales rise 20% in Q4. He expects Sagent to launch between 12 and 16 new products this year after launching a dozen last year. Yordon also says the company's new Chinese plant is already FDA-approved and manufacturing products, and he has high expectations for Sagent's research center in Chengdu China.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

More from Video

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Elon Musk's Twitter Tirade Is the Dumbest Thing on Wall Street

Elon Musk's Twitter Tirade Is the Dumbest Thing on Wall Street

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home